Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 6
  • 5
  • 9
  • 22
  • 3
  • 3
  • 19

Found 22 lancaster-general-health trials

A listing of lancaster-general-health medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World (DISCOVER-HCM)

Insights in Hypertrophic Cardiomyopathy and Observational Outcomes in Real World (DISCOVER-HCM)

18-99 years
All genders
Phase 4
The purpose of this registry is to understand the safety and effectiveness of various medications used in treating the condition of symptomatic obstructive hypertrophic cardiomyopathy (HCM), a type of heart disease that causes the muscular wall in the chambers of the heart to thicken which can cause blood flow in …
 Parasympathetic Augmentation via Respiratory Training for Patients with Systolic Heart Failure

Parasympathetic Augmentation via Respiratory Training for Patients with Systolic Heart Failure

18-99 years
All genders
Phase 4
The purpose of this study is to evaluate the effect of breath training on patients with systolic heart failure. The study evaluates patients and incorporates the use of smart phone technology for breath training at baseline and at three and six months, using the 6-minute walk test, a standard heart …
 Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

18-99 years
All genders
The purpose of this study is to evaluate if closing off the left atrial appendage (LAA) of your heart (a small-sack like structure that is part of the upper chamber of the heart) during scheduled heart surgery with a surgical device known as the AtriClip, reduces the risk of a …
 MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC

MK-7684A-006: Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab with Pembrolizumab) in Combination with Concurrent Chemoradiotherapy followed by MK-7684A Versus Concurrent Chemoradiotherapy followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III NSCLC

18-100 years
All genders
Phase 3
This trial is testing MK-7684A when given in combination with chemotherapy plus radiation therapy (concurrent chemoradiotherapy or cCRT). This trial is for people with stage 3 non-small cell lung cancer (NSCLC). Receiving cCRT is part of the standard treatment for patients with stage 3 NSCLC. MK-7684A, an experimental treatment, is …
 A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)

A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)

18 years and older
Female
Phase 2
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability  of luveltamab tazevibulin in …
 CLASS-HF: Consistently Assess Signs and Symptoms of Heart Failure

CLASS-HF: Consistently Assess Signs and Symptoms of Heart Failure

18-90 years
All genders
The purpose of this study is to examine the reliability and validity of the New York Heart Association (NYHA) Classification Guide that was developed to assist providers in appropriately assigning a functional class to their patients with heart failure. We will be evaluating the NYHA Classification guide against the 6-minute …
 OPTIMIZER PAS: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy (PAS)

OPTIMIZER PAS: Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy (PAS)

18-100 years
All genders
The OPTIMIZER Smart Post-Approval Study (PAS) is a single arm open label study of 620 participants receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%.
 MARVEN: Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy

MARVEN: Clinical, Electrocardiographic, and Cardiac Magnetic Resonance Imaging Risk Factors Associated with Ventricular Tachyarrhythmias in Nonischemic Cardiomyopathy

21-100 years
All genders
The purpose of this study is to learn what clinical, cardiac magnetic resonance imaging (CMR), and ECG factors could better identify which nonischemic cardiomyopathy (NICM) patients might develop rapid irregular heartbeats. This would then better identify who needs to get a CRT-D device. The study enrolls patients with NICM whose …
 FACT-CRT: Factors Associated with Response to Cardiac Resynchronization Therapy in Heart Failure Patients with Non-LBBB ECG Pattern

FACT-CRT: Factors Associated with Response to Cardiac Resynchronization Therapy in Heart Failure Patients with Non-LBBB ECG Pattern

18-100 years
All genders
This research study seeks to validate how echocardiogram (echo) data predicts response to cardiac resynchronization therapy (CRT) provided by a CRT device with a defibrillator (CRT-D) in individuals without the heart arrhythmia abnormality left bundle branch block (LBBB). It also aims to identify new variables recorded from electrocardiograms (ECG) or …
 HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

HERMES: Effects of Ziltivekimab Versus Placebo on Morbidity and Mortality in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Systemic Inflammation

18-100 years
All genders
Phase 3
This study will determine if ziltivekimab, a monoclonal antibody, can be used to treat people living with heart failure and inflammation. Previous studies showed that ziltivekimab can lower inflammation, which may have a positive effect on heart failure symptoms. The HERMES study will look more into this effect. Also, the …
1 - 10 of 22